Actos Patent Found Non-Obvious
This article was originally published in The Pink Sheet Daily
Executive Summary
Takeda's primary active ingredient patent for type 2 diabetes therapy Actos (pioglitazone) is valid and infringed by Mylan's and Alphapharm's ANDAs, a Manhattan federal judge ruled